Chaitanya Erady is a policy analyst in the biomedical science division at PHG. She is passionate about exploring the potential of upcoming omics-based technologies in revolutionising the healthcare industry, and how health-related data is managed and protected to ensure timely, equitable patient care.
At PHG, Chaitanya has contributed to a range of initiatives, including leading a company-wide horizon-scanning program, evaluating large-scale international genome projects, generating evidence through systematic reviews of novel biomarkers for personalized medicine, and conducting market analyses for novel drugs. She has also contributed to consultations for the NHS and other UK-based organisations on the future of omics technologies, and worked on assessing the potential of AI and novel computing methods in accelerating healthcare delivery.
Chaitanya earned her PhD at the University of Cambridge, where she investigated how omics-based technologies—genomics, transcriptomics, and proteomics—could improve understanding of neuropsychiatric disorders such as schizophrenia, bipolar disorder and depression. Previous experience include placements at the Cambridge Rare Disease Network (CRDN), Cambridge iTeams and as a senior analyst at a student-run think tank – Good data initiative, Cambridge – where she explored how digital technologies and their adoption have helped mental health diagnosis, and reported on the future of digital healthcare systems in African countries.
